The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
Edith A. Perez
No relevant relationships to disclose
Jose Manuel Lopez-Vega
Consultant or Advisory Role - Roche
Lucia Del Mastro
Honoraria - Roche
Thierry Petit
Consultant or Advisory Role - Roche (U)
Lada Mitchell
Employment or Leadership Position - Roche
Christina H. Pelizon
Employment or Leadership Position - Roche
Stock Ownership - Roche
Michael Andersson
Honoraria - Roche